AstraZeneca: Don’t Write Off Fasenra In COPD Just Yet

 
• By Andrew McConaghie

AstraZeneca's R&D leader admits mistakes in earlier failed Phase III trials. A new study will target the high eosinophil sub-group.

Eosinophil
Eosinophils in action: AstraZeneca is trying again in COPD • Source: Shutterstock

More from Respiratory

More from Therapy Areas